Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Nicholas Fisher is active.

Publication


Featured researches published by Nicholas Fisher.


Blood | 2008

Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction

Steven M. Devine; Ravi Vij; Michael P. Rettig; Laura Todt; Kiley McGlauchlen; Nicholas Fisher; Hollie Devine; Daniel C. Link; Gary Calandra; Gary Bridger; Peter Westervelt; John F. DiPersio

Allografts from HLA-matched sibling donors were mobilized and collected without granulocyte colony-stimulating factor (G-CSF) using AMD3100, a direct antagonist of CXCR4/stromal-derived factor 1 (SDF-1/CXCL12). Donors (N = 25) were treated with AMD3100 at a dose of 240 mug/kg by subcutaneous injection, and leukapheresis was then initiated just 4 hours later. Two-thirds of the donors collected an allograft with a CD34(+) cell dose sufficient for transplantation after just one dose of AMD3100. No donor experienced more than grade 1 toxicity. After a myeloablative regimen, 20 patients with hematologic malignancies received allografts collected after AMD3100 alone. All patients engrafted neutrophils (median day 10) and platelets (median day 12) promptly. Acute graft-versus-host disease (GVHD) grades 2 through 4 occurred in 35% of patients. One patient died due to complications related to acute GVHD. No unexpected adverse events were observed in any of the recipients. All 14 patients surviving in remission have robust trilineage hematopoiesis and are transfusion-free with a median follow-up of 277 days (range, 139-964 days). Direct antagonism of CXCR4 by AMD3100 may provide a more rapid and possibly less toxic and cumbersome alternative to traditional G-CSF-based mobilization in normal donors. This trial was registered as no. NCT00241358 at www.ClinicalTrials.gov.


Bone Marrow Transplantation | 2009

Bortezomib administered pre-auto-SCT and as maintenance therapy post transplant for multiple myeloma: a single institution phase II study.

Geoffrey L. Uy; Sagun D. Goyal; Nicholas Fisher; Aarti Oza; Michael H. Tomasson; Keith Stockerl-Goldstein; John F. DiPersio; Ravi Vij

The appropriate induction therapy before and the role of maintenance therapy after auto-SCT for patients with multiple myeloma remain areas of active investigation. We conducted a study in 40 patients with bortezomib given sequentially pre-auto-SCT and as maintenance therapy post auto-SCT. Pre-transplant bortezomib was administered for two cycles followed by high-dose melphalan 200 mg/m2 with auto-SCT of G-CSF-mobilized PBMCs. Post transplant bortezomib was administered weekly for 5 out of 6 weeks for six cycles. No adverse effects were observed on stem cell mobilization or engraftment. An overall response rate of 83% with a CR+very good partial remission (VGPR) of 50% was observed with this approach. Three-year Kaplan–Meier estimates of disease-free survival and overall survival (OS) were 38.2 and 63.1%, respectively. Bortezomib reduced CD8+ cytotoxic T cell and CD56+ natural killer cell PBL subsets and was clinically associated with high rates of viral reactivation to varicella zoster.


Cancer Chemotherapy and Pharmacology | 2008

Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)

Amanda F. Cashen; Ajit Shah; Laura Todt; Nicholas Fisher; John F. DiPersio


Clinical Lymphoma, Myeloma & Leukemia | 2007

Bortezomib Inhibits Osteoclast Activity in Patients with Multiple Myeloma

Geoffrey L. Uy; Rachna Trivedi; Shachar Peles; Nicholas Fisher; Qin Zhang; Michael H. Tomasson; John F. DiPersio; Ravi Vij


Biology of Blood and Marrow Transplantation | 2006

Bortezomib prior to autologous transplant in multiple myeloma: Effects on mobilization, engraftment, and markers of immune function

Geoffrey L. Uy; Shachar Peles; Nicholas Fisher; Michael H. Tomasson; John F. DiPersio; Ravi Vij


Blood | 2005

A Phase I Pharmacokinetic Trial of Decitabine Administered as a 3-Hour Infusion to Patients with Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS).

Amanda F. Cashen; Ajit Shah; Angela Helget; Laura Todt; Nicholas Fisher; John F. DiPersio


Archive | 2013

John Wilmot, Earl of Rochester : the poems and Lucina's rape

Keith Walker; Nicholas Fisher


Blood | 2004

Bortezomib Given in Sequence with Anthracycline and Thalidomide-Containing Regimens Does Not Adversely Affect Stem Cell Mobilization and Engraftment in Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation.

Geoffrey L. Uy; Nicholas Fisher; Steven M. Devine; Khoury H; Douglas Adkins; Michael H. Tomasson; Timothy A. Graubert; John F. DiPersio; Ravi Vij


Blood | 2005

Bortezomib (Velcade) When Given Pretransplant and Once Weekly as Consolidation Therapy Following High Dose Chemotherapy (HDCT) Leads to High Rates of Reactivation of Varicella Zoster Virus (VZV).

Shachar Peles; Nicholas Fisher; Steven M. Devine; Michael H. Tomasson; John F. DiPersio; Ravi Vij


Blood | 2006

HLA-Matched Sibling Donor Stem Cell Mobilization Can Be Safely and Effectively Reduced from a Five Day to a One Day Process by a Direct Antagonist of the CXCR4/SDF-1 Interaction.

Steven M. Devine; Ravi Vij; Laura Todt; Kiley McLaughlin; Nicholas Fisher; Natalie Morris; Daniel C. Link; Gary Calandra; Gary J. Bridger; John F. DiPersio

Collaboration


Dive into the Nicholas Fisher's collaboration.

Top Co-Authors

Avatar

John F. DiPersio

Washington University in St. Louis

View shared research outputs
Top Co-Authors

Avatar

Ravi Vij

Washington University in St. Louis

View shared research outputs
Top Co-Authors

Avatar

Michael H. Tomasson

Washington University in St. Louis

View shared research outputs
Top Co-Authors

Avatar

Steven M. Devine

Washington University in St. Louis

View shared research outputs
Top Co-Authors

Avatar

Geoffrey L. Uy

Washington University in St. Louis

View shared research outputs
Top Co-Authors

Avatar

Laura Todt

Washington University in St. Louis

View shared research outputs
Top Co-Authors

Avatar

Shachar Peles

Washington University in St. Louis

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ajit Shah

Washington University in St. Louis

View shared research outputs
Researchain Logo
Decentralizing Knowledge